{
    "clinical_study": {
        "@rank": "105900", 
        "acronym": "DIREBT", 
        "arm_group": [
            {
                "arm_group_label": "Bacteremia Positive Patients", 
                "description": "Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).\nAcinetobacter baumannii\nStaphylococcus aureus\nKlebsiella pneumonia\nPseudomonas aeruginosa\nEnterococcus faecalis\nEnterococcus faecium"
            }, 
            {
                "arm_group_label": "Bacteremia Negative Patients", 
                "description": "Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood specimens, in addition to bacterial isoaltes"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To assure the uniform collection, handling, storage and transport of patient whole blood\n      specimens and associated information to support validation of the T2 Bacteremia Assay."
        }, 
        "brief_title": "Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bacteremia", 
        "condition_browse": {
            "mesh_term": "Bacteremia"
        }, 
        "detailed_description": {
            "textblock": "This protocol is intended for use by external sites collecting clinical research specimens\n      for T2 Biosystems' use in developing the T2Bacterial Assay. Specimens and information on\n      patients' medical history, blood properties, medications, and blood culture history/results\n      are required from the T2Bacterial Assay's target patient population (i.e., candidates for\n      blood culture). Ideally, clinical specimens for use in developing the T2Bacterial Assay will\n      be collected from negative blood culture, positive non-bacteria blood culture and positive\n      bacteria blood culture patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject or subject's authorized representative must be able to understand, read and\n             sign the study specific informed consent form after the nature of the study has been\n             fully explained to them.\n\n          -  Males and females 18 - 95 years of age.\n\n        For Group A,\n\n          -  Subject is confirmed to have bacteremia  (gram negative rods, gram negative\n             coccobacillus, and/or gram positive cocci) as evidenced by a positive diagnostic\n             blood culture\n\n          -  Subsequent species identification identifies the presence of one of the following 6\n             species of bacteria:\n\n          -  Acinetobacter baumannii\n\n          -  Staphylococcus aureus\n\n          -  Klebsiella pneumonia\n\n          -  Pseudomonas aeruginosa\n\n          -  Enterococcus faecalis\n\n          -  Enterococcus faecium\n\n        For Group B,\n\n          -  Males and females 18 - 95 years of age.\n\n          -  Subject is confirmed to not have bacteremia from the 6 bacteria species targeted by\n             this study, as evidenced by diagnostic blood culture and subsequent species\n             identification.\n\n        Exclusion Criteria:\n\n          -  Use of any novel (i.e. not commercially available) drug compound within 30 days prior\n             to the collection of T2 blood specimens.\n\n          -  Subject has other co-morbid condition(s) that, in the opinion of the Investigator,\n             could limit the subject's ability to participate in the study or impact the\n             scientific integrity of the study.\n\n          -  Subject has had an anti-bacterial drug administered through the same port or central\n             line as is used to collect the clinical research specimens. A line draw cannot be\n             used to obtain a study sample if an antibacterial agent was administered\n             intravenously within the last 72 hours, unless the site can  specifically document\n             that a different line was used to administer the anti-bacterial agent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with blood culture results are eligible to participate"
            }
        }, 
        "enrollment": {
            "#text": "700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919762", 
            "org_study_id": "PRO-00191"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bacteremia", 
            "Sepsis", 
            "Acinetobacter baumannii", 
            "Staphylococcus aureus", 
            "Klebsiella pneumonia", 
            "Pseudomonas aeruginosa", 
            "Enterococcus faecalis", 
            "Magnetic Relaxation Detection", 
            "Nuclear Magnetic Resonance Detection", 
            "Blood culture"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "email": "pileggi-mary@cooperhealth.edu", 
                "last_name": "Mary Pileggi", 
                "phone": "856-757-9783"
            }, 
            "facility": {
                "address": {
                    "city": "Camden", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08103"
                }, 
                "name": "Cooper Medical School"
            }, 
            "investigator": {
                "last_name": "Annette Reboli, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)-Part I (Prospective Collection and Freezing of Whole Blood Specimens)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of bacteria positive patients based on concordant, sequential blood culture results and a positive T2 signal", 
            "measure": "Number of bacteremia positive patients", 
            "safety_issue": "No", 
            "time_frame": "3-5 days post blood culture"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of negative bacteremia samples based on concordant, sequential blood culture results and a negative T2 signal", 
            "measure": "Number of bacteremia negative patients", 
            "safety_issue": "No", 
            "time_frame": "3-5 Days post blood culture"
        }, 
        "source": "T2 Biosystems", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "T2 Biosystems", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}